Rhythm Pharmaceuticals, Inc. (RYTM) Stock Price & Analysis

Rhythm Pharmaceuticals, Inc. (RYTM) fell 2.05% to USD 102.74 as of September 8, 2026 at 05:44 UTC, according to Nexqual real-time market data.

RYTM last closed at USD 102.74; the session ranged USD 101.25–105.71 on volume of 466,906 shares. Market capitalization is —, with a 52-week range of USD 74.5–122.2 (NGM). Source: Nexqual, September 8, 2026 at 05:44 UTC.

Key Statistics (as of September 8, 2026 at 05:44 UTC)

Technical Analysis (RYTM)

Nexqual's technical model rates RYTM "SELL" based on 1 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 05:44 UTC.

From Rhythm Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• We have established a strong global foundation with IMCIVREE (setmelanotide), which has achieved regulatory approvals and marketing authorization, reimbursed access or named patient sales in more than 25 countries, including the United States, the European Union and the United Kingdom.
• The EMA confirmed validation of our Type II variation submission to the Marketing Authorization Application (MAA) for setmelanotide for the same indication.
• These estimates are based on our patient identification efforts in the United States and Europe and our proprietary genetic sequencing data, as well as our belief that BBS, like most rare diseases, is underdiagnosed.
• We also expect EMANATE results, in combination with results from our completed DAYBREAK trial, to advance our understanding of which genetic variants are associated with loss of function and to inform on our approach to future clinical development.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:44 UTC. This page is informational and not investment advice.